China Medicine Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHME research report →
Price Chart
About the company
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.
- CEO
- Senshan Yang
- IPO
- 2006
- Employees
- 281
- HQ
- Guangzhou, GD, CN
Get TickerSpark's AI analysis on CHME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $499.80K
- P/E
- -49.08
- PEG
- -0.50
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -16.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,477
- Net Income
- $-7,477+0.0%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- -8.66
- RSI (14)
- 36
- Avg Volume
- 16.17K
No earnings-call transcripts are available for CHME yet.
- Free Float
- 65.0%
- Shares Outstanding
- 23.80M
- Float Shares
- 15.47M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 10 | Shao Sean | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHME coverage
Recent articles, reports, and earnings notes.
No research on CHME yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHME report →